RA
VVOS icon

Royce & Associates’s Vivos Therapeutics VVOS Stock Holding History

Royce & Associates’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-13,920
Closed -$1.72M – 1020
2021
Q2 		$1.72M Hold
13,920
– – 0.01% 782
2021
Q1 		$2.31M Buy
13,920
+1,920
+16% +$343K 0.02% 734
2020
Q4 		$1.77M Buy
+12,000
New +$2.19M 0.01% 748

Other funds holding VVOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIA
Avalon Investment & Advisory Houston, Texas $3.65B AUM 0.47% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Royce & Associates's VVOS Position: Q3 2021 in Review

Royce & Associates sold out of Vivos Therapeutics (VVOS) in Q3 2021, closing a stake of 13,920 shares — an estimated $1.72M sold.

Royce & Associates first reported a position in VVOS in Q4 2020 and held it in 3 quarters. The position peaked at $2.31M in Q1 2021. 37 funds tracked by Wall St. Rank hold VVOS as of Q3 2021.

  • Royce & Associates reported no remaining Vivos Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Royce & Associates sold 13,920 Vivos Therapeutics shares in Q3 2021, an estimated $1.72M.
  • Royce & Associates first reported a position in Vivos Therapeutics in Q4 2020 and held it in 3 quarters.
  • Royce & Associates's Vivos Therapeutics position peaked at $2.31M in Q1 2021.
  • 37 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q3 2021.

Based on Royce & Associates's 13F filing for Q3 2021, filed 10 Nov 2021.